MAGELLAN: Rivaroxaban for VTE Prevention

Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Bayer. Primary endpoints: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days and Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 10 + 5 Days. Started Dec 2007; status: completed.